Immunovirological parameters and cytokines in HIV infection;Parâmetros imunovirológicos e citocinas na infecção pelo HIV

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 45, Issue 6, 2012, Pages 663-669

  Tasca, Karen Ingrid ^a   Calvi, Sueli Aparecida ^a   Do Rosário de Souza, Lenice ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Antiretroviral therapy; Clinical stages of infection; Cytokines; HIV AIDS

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PROGNOSIS; REVIEW; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TH17 CELL; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 84872294911     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0037-86822012000600002     Document Type: Review

References (109)

1. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de DST e AIDS. Boletim epidemiológico - AIDS e DST. Ano IV. Brasília: Ministério da Sáude; 2007.
2. Vaishnav YN, Wong-Staal F. The Biochemistry of Aids. Annu Rev Biochem 1991; 60:577-630.
3. Mellors J, Rinaldo C, Gupta P. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170.
4. Coordenação Estadual de DST/AIDS [Internet]. Governo do Estado do Pará; [Cited 2011 April]. Available from: http://www.saude.pa.gov.br/.
5. Lifson AR, Hessol NA, Rutherford GW. Progression and clinical outcome of infection due to human immunodeficiency virus. Clin Infect Dis 1992;14:966-972.
6. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunologic progression. AIDS 1994; 8:1123-1128.
7. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332:209-216.
8. Okulicz JF, Marconi VC, Landrum ML, Wegner S, Weintrob A, Ganesan A, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV Natural History Study. J Infect Dis 2009; 200:1714-1723.
9. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, et al. HIV-specific CD8 T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3:1061-1068.
10. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
11. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300.
12. Mavigner M, Delobel P, Cazabat M, Dubois M, L'Faqihi-Olive FE, Raymond S, et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS ONE 2009; 4:e7658.
13. Villacres MC, Kono N, Mack WJ, Nowicki MJ, Anastos K, Augenbraun M, et al. Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infection. J Infect Dis 2012; 206:780-789.
14. Davey RT Jr, Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999; 96:15109-15114.
15. Peçanha EP, Antunes OAC, Tanuri A. Estratégias farmacológicas para a terapia anti-AIDS. Química Nova 2002; 25:1108-1116.
16. Souza MVN, Almeida MV. Drogas anti-VIH: passado, presente e futuras erspectivas. Química Nova 2003; 26:366-373.
17. LaBonte J, Lebbos J, Kirkpatrick P. Efuvirtide. Nat Rev Drug Discov 2003; 2:345.
18. Ciccosanti F, Corazzani M, Soldani F, Matarrese P, Pagliarini V, Iadevaia V, et al. Proteomic analysis identifies prohibitin down-regulation as a crucial event in the mitochondrial damage observed in HIV-infected patients. Antiv Ther 2010; 15:377-390.
19. Gutierrez M, Mateo GM, Vidal F, Domingo P. The toxicogenetics of antirretroviral therapy: the evil inside. Curr Med Chem 2011; 18:209-219.
20. Sousa AE. Citocinas e HIV - Revisão do tema através da análise a nível celular individualizado. II Congresso Virtual HIV/AIDS: Ontem, Hoje e Amanhã. [Cited 2011 June]. Available from: http://www.aidscongress.net/article.php?id_comunicacao=82/.
21. Pantaleo G. How immune-based interventions can change HIV therapy. Nat Med 1997; 3:483-486.
22. Imami N, Antonopoulos C, Hardy GA, Gazzard B, Gotch FM. Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. AIDS Res Hum Retrov 1999; 15:1499-1508.
23. Gianella S, von Wyl V, Fischer M, Niederost B, Battegay M, Bernasconi E, et al. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther 2011; 16:535-545.
24. Bowman MC, Archin NM, Margolis DM. Pharmaceutical approaches to eradication of persistent HIV infection. Expert Rev Mol Med 2009; 11:e6.
25. Fidler S, Ewings F, Porter K, Cooper D, Tambussi G, et al. A comparison of HIV viral rebound following ART cessation in primary and chronic HIV infection. Paper presented at: 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA. February 16-19, 2010; [#474] San Francisco, CA.
26. Pereira CCA, Machado CJ, Rodrigues RN. Perfis de causas múltiplas de morte relacionadas ao HIV/AIDS nos municípios de São Paulo e Santos, Brasil, 2001. Cad Saude Publica 2007; 23:645-655.
27. Cozzi-Lepri A, French MA, Baxter J, Okhuysen P, Plana M, Neuhaus J, et al. Resumption of HIV replication is associated with monocyte/ macrophage derived cytokine and chemokine changes: results from a large international clinical trial. AIDS 2011; 25:1207-1217.
28. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543.
29. Dubé MP, Sattler FR. Inflammation and complications of HIV disease. J Infect Dis 2010; 201:1783-1785.
30. Keating SM, Jacobs ES, Norris PJ. Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development. Cytokine Growth F R 2012; 23: 193-206
31. Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother 2001; 12: 133-150.
32. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA 1989; 86:1336-1340.
33. Haissman JM, Vestergaard LS, Sembuche S, Erikstrup C, Mmbando B, Mtullu S, et al. Plasma Cytokine Levels in Tanzanian HIV-1-Infected Adults and the Effect of Antiretroviral Treatment. J Acquir Immune Defic Syndr 2009; 52:493-497.
34. Han X, Becker K, Degen HJ, Jablonowski H, Strohmeyer G. Synergistic stimulatory effects of tumour necrosis factor alpha and interferon gamma on replication of human immunodeficiency virus type 1and on apoptosis of HIV-1-infected host cells. Eur J Clin Invest 1996; 26:286-292.
35. Munoz-Fernandez MA, Navarro J, Garcia A, Punzón C, Fernández-Cruz E, Fresno M. Replication of human immunodeficiency virus-1 in primary human T cells is dependent on the autocrine secretion of tumor necrosis factor through the control of nuclear factor-kappa B activation. J Allergy Clin Immunol 1997; 100:838-845.
36. Roberts L, Passmore JS, Williamson C, Little F, Bebell LM, Mlisana K, et al. Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS 2010; 24:819-831.
37. Norris PJ, Pappalardo BL, Custer B, Spotts G, Hecht FM, Busch MP. Elevations in IL-10, TNFα, and IFN-γ from the earliest point of HIV Type 1 infection. AIDS Res Hum Retrov 2006; 22:757-762.
38. Rychert J, Strick D, Bazner S, Robinson J, Rosenberg E. Detection of HIV gp120 in plasma during early HIV infection is associated with increased proinflammatory and immunoregulatory cytokines. AIDS Res Hum Retrov 2010; 26:1139-1145.
39. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998; 70:83-243.
40. Vassena L, Proschan M, Fauci AS, Lusso P. Interleukin 7 reduces the levels of spontaneous apoptosis in CD4+ and CD8+ T cells from HIV-1-infected individuals. Proc Natl Acad Sci USA 2007; 104:2355-2360.
41. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83: 3719-3733.
42. Eberly MD, Kader M, Hassan W, Rogers KA, Zhou J, Mueller YM, et al. Increased IL-15 production is associated with higher susceptibility of memory CD4 T cells to simian immunodeficiency virus during acute infection. J Immunol 2009; 182:1439-1448.
43. Wren L, Parsons MS, Isitman G, Center RJ, Kelleher AD, Stratov I, et al. Influence of cytokines on HIV-specific antibody-dependent cellular cytotoxicity activation profile of natural killer cells. PLoS ONE 2012; 7:e38580.
44. Clerici M, Shearer GM. A TH-1/TH-2 switch is a critical step in etiology of HIV infection. Immunol Today 1993; 14:107-111.
45. Clerici M, Sarin A, Coffman RL, Wynn TA, Blatt SP, Hendrix CW, et al. Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis. Proc Natl Acad Sci USA 1994; 91:11811-11815.
46. Estes JD, Wietgrefe S, Schacker T, Southern P, Beilman G, Reilly C, et al. Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor beta 1-positive regulatory T cells and begins in early infection. J Infect Dis 2007; 195:551-561.
47. Huang J, Burke PS, Cung TD, Pereyra F, Toth I, Walker BD, et al. Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers. J Virol 2010; 84:9463-9471
48. Redda AD, Dabitaob D, Breamb JH, Charvat B, Laeyendecker O, Kiwanuka N, et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. PNAS 2009; 106:6718-6723.
49. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:4781-4789.
50. Li Y, Ling W, Xu H, Wang M, Wu C. The activation and dynamics of cytokine expression by CD4+ T cells and AIDS progression in HIV-1-infected Chinese individuals. Microb Pathogenesis 2012; 53:189-197.
51. French MA, King MS, Tschampa JM, Silva BA, Landay AL. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis 2009; 200:1212-1215.
52. Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS 2010; 5:498-503.
53. Kamat A, Misra V, Cassol E, Ancuta P, Yan Z, Li C, et al. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS ONE 2012; 7:e30881.
54. Gay C, Dibben O, Anderson JA, Stacey A, Mayo AJ, Norris PJ, et al. Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS ONE 2011; 6:e19617.
55. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
56. Regidor DL, Detels R, Breen EC, Widney DP, Jacobson LP, Palella F, et al. Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS 2011, 25:303-314.
57. Stylianou E, Aukrust P, Kvale D, Müller F, Frøland SS. IL-10 in HIV infection: increasing serum IL-10 levels with disease progression-down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol 1999; 116:115-120.
58. Sachdeva RK, Wanchu A, Bagga R, Malla N, Sharma M. Effect of non-nucleoside reverse transcriptase inhibitors on cytokine, chemokine, and immunoglobulin profiles in serum and genital secretions of HIV-infected women. J Interferon & Cytokine Res 2010; 30:299-310.
59. Negredo E, Massanella M, Puig J, Pérez-Alvarez N, Gallego-Escuredo JM, Villarroya J, et al. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis 2010; 50:1300-1308.
60. Resino S, Belloan JM, Sanchez-Ramoa AS, Gurbindo D, Muñóz-Fernandez MA. Clinical relevance of cytokine production in HIV-1 infection in children on antiretroviral therapy. Scand J Immunol 2000; 52:634-640.
61. Moore KW, O' Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993; 11:165-190.
62. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150:353-360.
63. Barqasho B, Nowak P, Tjernlund A, Kinloch S, Goh LE, Lampe F, et al. Kinetics of plasma cytokines and chemokines during primary HIV-1 infection and after analytical treatment interruption. British HIV Association. HIV Med 2009; 10:94-102.
64. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214:231-241.
65. Autran B, Carcelain G, Debre P. Immune reconstitution after highly active anti-retroviral treatment of HIV infection. Adv Exp Med Biol 2001; 495:205-212.
66. Meira DA, Almeida RAMB, Barbosa NA, Souza LR, Olivo TET, Henriques RMS, et al. Assessment of cytokine values in serum by RT-PCR in HIV-1 infected individuals with and without highly active anti-retroviral therapy (HAART). J Venom Anim Toxins incl Trop Dis 2008; 14:685-702.
67. Orsilles MA, Pieri E, Cooke P, Caula C. IL-2 and IL-10 serum levels in HIV-1-infected patients with or without active antiretroviral therapy. APMIS 2006; 114:55-60.
68. Shearer GM, Clerici M. Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today 1996; 17:21-24.
69. Wiercinska-Drapalo A, Jaroszewicz J, Flisiak R, Prokopowicz D. Plasma interleukin-18 is associated with viral load and disease progression in HIV-1-infected patients. Microbes Infect 2004; 6:1273-1277.
70. Torre D, Pugliese A. Interleukin-18: a proinflammatory cytokine in HIV-1 infection. Curr HIV Res 2006; 4:423-430.
71. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Herpin B, Metcalf JA, et al. Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med 2001; 194:1731-1741.
72. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol 2006; 7:235-239.
73. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004; 190:624-631.
74. Ye P, Garvey PB, Zhang P, Nelson S, Bagby G, Summer WR, et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol 2001; 25:335-340.
75. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007; 13:11-718.
76. Steinman L. A rush to judgment on Th17. J Exp Med 2008; 205:1517-1522.
77. Maek-A-Nantawat W, Buranapraditkun S, Klaewsongkram J, Ruxrungthum K. Increased interleukin-17 production both in helper T Cell subset Th17 and CD4-negative T cells in human immunodeficiency virus infection. Viral Immunol 2007; 20:328.
78. Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 2003; 170:2106-2112.
79. Shin HC, Benbernou N, Esnault S, Guenounou M. Expression of IL-17 in human memory CD45RO_ T lymphocytes and its regulation by protein kinase A pathway. Cytokine 1999; 11:257-266.
80. Sofi MH, Liu Z, Zhu L, Yu Q, Kaplan MH, Chang CH. Regulation of IL-17 expression by the developmental pathway of CD4 T cells in the thymus. Mol Immunol 2010; 47:1262-1268.
81. Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, Luger D, et al. Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol 2008; 180:5167-5171.
82. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27:485-517.
83. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008; 454:350-352.
84. Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 2007; 19:652-657.
85. Hou W, Kang HS, Kim BS. Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection. J Exp Med 2009; 206: 313-328.
86. Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007; 448:484-487.
87. Barker BR, Parvani JG, Meyer D, Hey AS, Skak K, Letvin NL. IL-21 induces apoptosis of antigen-specific CD8+ T lymphocytes. J Immunol 2007; 179:3596-3603.
88. Hed AE, Khaitan A, Kozhaya L, Manel N, Daskalakis D, Borkowsky W, et al. Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J Infect Dis 2010; 201:843-854.
89. Brenchley JM, Paiardini M, Knox KS, Asher AI, Cervasi B, Asher TE, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008; 112:2826-2835.
90. Ciccone W, Thompson J, Greenwald J, Hodge J, Lee P, Yao M, et al. CD4 T cell populations, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1 infected LTNP. 17th Conference on Retroviruses and Opportunistic Infections. Abstract 373, 2010.
91. Cecchinato V, Trindade CJ, Laurence A, Heraud JM, Brenchley JM, Ferrari MG, et al. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol 2008; 1: 279-288.
92. Salgado M, Rallón NI, Rodés B, López M, Soriano V, Benito JM. Long-term non-progressors display a greater number of Th17 cells than HIV-infected typical progressores. Clin Immunol 2011;139:110-114.
93. Favre D, Lederer S, Kanwar B, Ma ZM, Proll S, Kasakow Z, et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. Plos Phatogens 2009; 2:e1000295.
94. Macal M, Sankaran S, Chun TW, Reay E, Flamm J, Prindiville TJ, Dandekar S. Effective CD4+ Tcell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol 2008; 1:475-488.
95. Kader M, Wang X, Piatak M, Lifson J, Roederer M, Veazey R, Mattapallil JJ. Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol 2009; 2:439-449.
96. MacDonald TT, Murch SH. Aetiology and pathogenesis of chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 1994; 8:1-34.
97. Heise C, Miller CJ, Lackner A, Dandekar S. Primary acute simian immunodeficiency virus infection of intestinal lymphoid tissue is associated with gastrointestinal dysfunction. J Infect Dis 1994; 169:1116-1120.
98. Cummins AG, LaBrooy JT, Stanley DP, Rowland R, Shearman DJ. Quantitative histological study of enteropathy associated with HIV infection. Gut 1990; 31: 317-321.
99. Clayburgh DR, Shen L, Turner JR. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 2004; 84:282-291.
100. Nigam P, Kwa S, Velu V, Amara RR. Loss of IL-17-Producing CD8 T Cells during Late Chronic Stage of Pathogenic Simian Immunodeficiency Virus Infection. J Immunol 2011; 186:745-753.
101. Gori A, Tincati C, Rizzardini G, Torti C, Quirino T, Haarman M, et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol 2008; 46:757-758.
102. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-1371.
103. Li Q, Estes JD, Duan L, Jessurun J, Pambuccian S, Forster C, et al. Simian immunodeficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection. J Infect Dis 2008; 197:420-429.
104. Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol 2001; 14:753-777.
105. Klatt NR, Brenchley JM. Th17 Cell Dynamics in HIV Infection. Curr Opin HIV AIDS 2010; 5:135-140.
106. Fonseca LC, Martins FL, Vieira RCPA, Pereira RMC, Ferreira AS, Raposo NRB. Evaluation of inadequate anti-retroviral treatment in patients with HIV/AIDS. Rev Soc Bras Med Trop 2012; 45:151-155.
107. Hunt PW. Th17, Gut, and HIV: Therapeutic implications. Curr Opin HIV AIDS 2010; 5:189-193.
108. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:1496-1498.
109. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma Levels of Soluble CD14 independently predict mortality in HIV infection. J Infect Dis Advance 2011; 203:780-790.